Verve Therapeutics Inc.

NASDAQ: VERV · Real-Time Price · USD
11.13
0.03 (0.27%)
At close: Jul 24, 2025, 3:59 PM

Verve Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
172.56M 206.18M 115.41M 64.33M
Short-Term Investments
351.72M 417.77M 439.4M 296.11M
Long-Term Investments
n/a n/a 4.82M 5.24M
Other Long-Term Assets
7.92M 6.94M 585K 2.7M
Receivables
3.25M 5.9M 1.01M n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
15.21M 8.1M 7.34M 6.69M
Total Current Assets
542.75M 637.95M 563.16M 367.13M
Property-Plant & Equipment
96.73M 107.8M 110.66M 9.06M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
104.64M 114.74M 116.06M 17M
Total Assets
647.39M 752.69M 679.22M 384.12M
Account Payables
4.52M 6.64M 2.42M 7.08M
Deferred Revenue
3.6M n/a 20.01M -12.99M
Short-Term Debt
10.44M n/a 11.9M 1.96M
Other Current Liabilities
14.3M 12.34M -261K 4.99M
Total Current Liabilities
42.91M 37.01M 35.09M 22.02M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
1.28M 2.91M 3.17M 4.75M
Total Long-Term Liabilities
111.08M 116.18M 93.2M 4.75M
Total Liabilities
153.99M 153.19M 128.29M 26.77M
Total Debt
69.98M 74.91M 81.92M 1.96M
Common Stock
89K 82K 62K 49K
Retained Earnings
-743.01M -544.3M -344.24M -186.85M
Comprehensive Income
428K 272K -694K -228K
Shareholders Equity
493.4M 599.5M 550.93M 357.35M
Total Investments
351.72M 417.77M 439.4M 296.11M